Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.

doi:10.1093/jnci/djq390

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.

Journal of the National Cancer Institute - 17 Nov 2010

Freedman Andrew N, Sansbury Leah B, Figg William D, Potosky Arnold L, Weiss Smith Sheila R, Khoury Muin J, Nelson Stefanie A, Weinshilboum Richard M, Ratain Mark J, McLeod Howard L, Epstein Robert S, Ginsburg Geoffrey S, Schilsky Richard L, Liu Geoffrey, Flockhart David A, Ulrich Cornelia M, Davis Robert L, Lesko Lawrence J, Zineh Issam, Randhawa Gurvaneet, Ambrosone Christine B, Relling Mary V, Rothman Nat, Xie Heng, Spitz Margaret R, Ballard-Barbash Rachel, Doroshow James H, Minasian Lori M

Abstract excerpt

Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individuals respond differently to drug therapy, in terms of both adverse effects and treatment efficacy. To identify research priorities as well as the resources and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cooperative Behavior

Share to Drug Approval

Share to Drug Design

Share to Information Dissemination

Share to Precision Medicine

Share to Survivors

Share to United States Food and Drug Administration

Source

Open in PubMed Open full text

Identifiers

PMID: 20944079
DOI: 10.1093/jnci/djq390
PMCID: PMC2982809

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.PMID 20944079Read ↗

Pharmacogenetics and pharmacogenomics of anticancer agents.Semantic proximity Read ↗

Cancer Pharmacogenomics: Early Promise, But Concerted Effort NeededSemantic proximity Read ↗

Cancer pharmacogenomics: implications on ethnic diversity and drug response.Semantic proximity Read ↗

Cancer pharmacogenetics.Semantic proximity Read ↗

Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.Semantic proximity Read ↗

Pharmacogenomics: An evolving clinical tool for precision medicine.Semantic proximity Read ↗

Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesSemantic proximity Read ↗

Cancer pharmacogenetics: polymorphisms, pathways and beyond.Semantic proximity Read ↗

Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet?Semantic proximity Read ↗

Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020.Semantic proximity Read ↗

Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicitySemantic proximity Read ↗

Application of genotype-guided cancer therapy in solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.